The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
25155913 |
32 |
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. |
Astrazeneca |
23121096 |
86 |
Ion channels as therapeutic targets: a drug discovery perspective. |
Pfizer |
22793372 |
66 |
Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor. |
Vanderbilt University Medical Center |
22910039 |
66 |
Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. |
Vanderbilt University Medical Center |
11170639 |
73 |
Current and novel approaches to the drug treatment of schizophrenia. |
Merck Sharp and Dohme Research Laboratories |
21296466 |
20 |
Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators. |
Hebei Medical University |
30869888 |
61 |
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease. |
TBA |
30538065 |
48 |
The discovery and optimization of benzimidazoles as selective Na |
Pfizer |
28626530 |
71 |
Discovery of a Series of Indazole TRPA1 Antagonists. |
Pfizer |